Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -3.8% according to Deutsche.
OXB.L
Deutsche set a target price of 380 GBX for the company, which when compared to the Oxford BioMedica plc share price of 395 GBX at opening today (15/11/2024) indicates a potential downside of -3.8%. Trading has ranged between 164 (52 week low) and 450 (52 week high) with an average of 179,628 shares exchanging hands daily. The market capitalisation at the time of writing is £435,873,145.
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.
Oxford BioMedica plc -3.8% potential downside indicated by Deutsche
- Written by: Charlotte Edwards
Latest Company News
Oxford Biomedica has introduced a fast-track development and manufacturing offering for AAV and lentiviral vectors, aiming to shorten the route to GMP manufacture and help biotech clients reach clinical milestones sooner.
Oxford Biomedica plc will hold its Capital Markets Day on 2 June 2026 in London and participate in several investor conferences between March and June 2026. The company will also report FY 2025 preliminary results on 26 March 2026, followed by a virtual analyst briefing.
Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes.
